Are you interested in participating in our trial? We are seeking physicians treating hospitalized COVID-19 patients. Our goal is to evaluate if high-dose intravenous immunoglobulin (IVIg) can stabilize or improve patient clinical status. Read more to learn the details of our trial, eligibility requirements, and how you and your COVID-19 patients may be able to take part in this important research.
Our trial is a randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate if high-dose IVIg therapy can stabilize or improve clinical status in patients with severe COVID-19 disease.
Immunomodulation in patients with severe COVID-19 disease to prevent deterioration of clinical status.
The primary objective of this study is to determine if high-dose IVIg therapy will stabilize or improve clinical status in patients with severe COVID-19 disease.
The secondary objective of this study is to measure the effects of a high-dose of IVIg on slowing or stopping the processes impacted by COVID-19, by improving pulmonary function, quality of life, and correlated impact on metabolic factors.
For more information or to learn how to become a clinical investigator in this trial, please contact:
Clinical Study Manager
Phone: +1 (201) 604-1124
Mobile: +1 (201) 417-1779